logo
Sign in

ALECTOR, LLC

SAN FRANCISCO, CA · Founded 2013 · Biotech · Public

Monoclonal antibodies and small molecules targeting neuroinflammation pathways for neurodegenerative diseases

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · alector.com

Sector
Biotech
Headquarters
SAN FRANCISCO, CA
Founded
2013
Latest Form D
$32.3M, Sep 2015
Total capital
$33.8M
Federal grants
$1.5M
2 awards · 2015–2016
Rank in peer group#182 of 326
Private capital raised
$32.3M
1 Form D · last Sep 2015
133 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
15
25 pending · first 2024
Rank in peer group#2 of 326

Capital timeline

20152016FEDERAL ↑EQUITY ↓Cumulative $33.8M$198K$1.3M1st Form D$32.3M
20152016FEDERAL ↑EQUITY ↓Cumulative $33.8M$198K$1.3M1st Form D$32.3M

Latest events

  • Federal grantHealth and Human S · Phase II · SORT1:PGRN blocking antibodies for Frontotemporal dementia$1.3M
  • Private capital raisedForm D · SEC · 1st filing$32.3M
  • Federal grantHealth and Human S · Phase II · SORT1:PGRN blocking antibodies for Frontotemporal dementia$198K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

<1months

from ALECTOR, LLC’s first federal award to its first private round.

First federal award · Sep 2015
Health and Human S · $198K
First Form D · Sep 2015
$32.3M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#2 · top 1%
  • Linked publications#11 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Arnon RosenthalResearcherExecutive Officer, DirectorLinked by $1.5M in grants as PI
  • Carl GordonDirectorNamed in SEC Form D filings
  • Terry McGuireDirectorNamed in SEC Form D filings
  • Tillman GerngrossDirectorNamed in SEC Form D filings

What it has protected

USPTO · 15 granted of 40
Show all 40 patent records

Recent research by its founders

  • Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN (LS2.002)20260 cites
  • Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer’s disease20253 cites
  • Integrative analysis of pooled CRISPR screens provide functional insights into AD GWAS risk genes20251 cites

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .